A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system.

Published

Journal Article

Bispecific T-cell engagers (BiTEs) may break multiple barriers that currently limit the use of immunotherapy in glioblastoma patients. We have recently described a novel BiTE specific for a mutated form of the epidermal growth factor receptor, EGFRvIII, that exerts potent antineoplastic effects against established invasive tumors of the brain.

Full Text

Duke Authors

Cited Authors

  • Choi, BD; Pastan, I; Bigner, DD; Sampson, JH

Published Date

  • April 1, 2013

Published In

Volume / Issue

  • 2 / 4

Start / End Page

  • e23639 -

PubMed ID

  • 23734318

Pubmed Central ID

  • 23734318

International Standard Serial Number (ISSN)

  • 2162-4011

Digital Object Identifier (DOI)

  • 10.4161/onci.23639

Language

  • eng

Conference Location

  • United States